Edward Weinstein, PhD
Co-Founder, President and CEO
Dr. Edward J. Weinstein was co-Founder and President of SAGE Labs, a life science contract research organization with a focus on genetic engineering, until it was acquired by Horizon Discovery in 2014. Edward continued at Horizon as President of the Research Services business unit until 2016. Prior to those roles, Edward served as Manager of R&D and Director of Operations in the Research Biotechnology business unit of Sigma-Aldrich. He has also worked in the pharmaceutical industry, leading molecular profiling portfolios for both Merck and Pfizer. Dr. Weinstein has earned a Ph.D. in genetics from Harvard University, a Masters of Medical Science from Harvard Medical School and bachelor degrees in Chemistry and Cellular-Molecular Biology from the University of Michigan.
Crystal Winkeler, PhD
Co-Founder and Chief Operating Officer
Dr. Crystal Winkeler has been a senior analyst for BioGenerator in St. Louis, MO, since 2013. Crystal has over 7 years of experience in biomedical research with expertise in the fields of cancer and bone biology. She received a B.S. in Molecular Biology from Bradley University, where she was involved in animal physiology research for 4 years. In 2011, Crystal received her Ph.D. in Molecular Cell Biology from Washington University in St. Louis. Crystal’s thesis research focused on analyzing the genetics of a mouse model for studying osteoclasts and the role of the ARF tumor suppressor in post-mitotic cells. During her academic career, she was also responsible for the critical review of scientific data spanning a broad spectrum of biomedical research. Additionally, Crystal has held leadership positions for a consulting company that works with biotechnology start-ups, where she focused on due diligence, market assessment, and interviewing key opinion leaders.
Kevin Gamber, PhD
Vice President of Marketing
Dr. Kevin Gamber joined Canopy Biosciences in 2017 as the Vice President of Marketing. Kevin has over 10 years of experience marketing products and services for biomedical research. Most recently, Kevin was at SAGE Labs (now Horizon Discovery), where he focused on developing and commercializing gene engineering services in cell lines and animal models, with applications in neuroscience, ADME/Tox, immunology, oncology, and cardiovascular disease. Kevin received his Ph.D. in Pharmacology and Physiology from St. Louis University School of Medicine in Dr. Thomas Westfall’s laboratory, and continued pursuing his interests in the neural control of energy balance as a post-doctoral fellow in Dr. Christian Bjørbæk’s laboratory at Harvard Medical School.
Jan Detmers, PhD
Head of Clinical Development
Jan Detmers cofounded Zellkraftwerk, GmbH and served as CEO until Zellkraftwerk joined Canopy Biosciences in 2019, where he is currently the Head of Clinical Development. Jan is a serial entrepreneur, with a history of leading several companies as CEO, including Chimera Biotec, Molzym, Mioco, and Park Venture Management. Prior, Jan received his PhD in Molecular Biology at the Max Planck Institute.
Christian Hennig, MD
Chief Scientific Officer
Christian Hennig cofounded Zellkraftwerk, GmbH and served as Chief Scientific Officer before Zellkraftwerk joined Canopy Biosciences in 2019, where he currently is the the CSO. Prior, Christian studied medicine at the Luebeck School of Medicine and worked as physician at different locations with a broad focus on immunology (transfusion medicine and immunology diagnostics, oncology, pediatrics/primary immunodeficiencies). His research focus is on B-cell immunology/antibodies and on new technologies and software solutions in life sciences (www.researchgate.net/profile/Christian_Hennig2).
Christian holds patents in 5 patent families generating double-digit annual revenues. Meanwhile, he founded and headed two companies developing cutting edge technologies in the live science sector: Genovoxx GmbH developed NextGen sequencing technology and novel nucleotides, Zellkraftwerk GmbH developed and markets a Chipcytometry technology.